The list recommending customs duty of 5% includes 74 drugs, while another suggesting full exemption has 69 drugs. A separate ...

A meeting held by the FDA Thursday spotlighted debate over black box warnings that have limited use of hormone treatment for ...

Emiltatug ledadotin shows promising antitumor activity in various cancers, with manageable safety, highlighting its potential ...

The drugs-some of which cost just shy of £3million per patient-can revolutionise and save the lives of a handful of people born with devastating illnesses each year.

The documents show that blockbuster cancer drugs like pembrolizumab (brand Keytruda), osimertinib (brand Tagrisso), and ...

Cancer Antibody Drug Conjugates Treatment Market USD 50 Billion Opportunity Says Kuick Research. Delhi, July 11, 2025 (GLOBE ...

In a phase 2 study, 52% of patients treated with Bria-IMT plus a checkpoint inhibitor for metastatic breast cancer were alive at one year.

Endometrial Cancer is a type of cancer that begins in the lining of the uterus, most commonly affecting postmenopausal women. Rising prevalence due to increasing obesity rates and aging population, ...

The main patent for Ohtuvayre, the COPD drug at the heart of Verona’s $10 billion sale, expired in 2020. For Merck to make ...

The FDA granted breakthrough therapy designation to first-line treatment with Enhertu plus Perjeta for unresectable or metastatic HER2+ breast cancer.

New data could make HER2-directed antibody-drug conjugate (ADC) Enhertu an option for previously untreated breast cancer for the first time.

But for metastatic HER2 low cancer, there were few additional options, until clinical trials showed Enhertu kept the cancer at bay better than other treatments.